{
  "abstract": "Background: Corrected QT interval (QTc) prolongation is a known risk for fatal cardiac arrythmias and emerged as a safety signal with currently approved menin inhibitors (all-grade: 12%–36%; high-grade: 8–17%). QTc prolongation may limit dose intensity of available menin inhibitor therapy and complicate management of AML by preventing combination with anti-leukemic therapies and use of critical supportive care medicines. Bleximenib is being evaluated in late stage clinical studies in relapsed/refractory or newly diagnosed KMT2A-rearranged or NPM1-mutated AML. We report cardiac safety analyses from two Phase 1 trials evaluating bleximenib as monotherapy (ALE1001 [NCT04811560]) or in combination with AML-directed therapies (ALE1002 [NCT05453903]). Methods: The safety population included 141 participants (pts) in ALE1001 and 193 in ALE1002. Patients were excluded for QTcF ≥450 ms (males) or ≥470 ms (females), or a family history of long QT syndrome. Bleximenib was administered orally in 28-day cycles at doses ranging from 50–100 mg QD or 15–150 mg BID, as monotherapy or combined with venetoclax/azacitidine (VEN/AZA) or intensive chemotherapy (7+3). Cardiac monitoring included triplicate 12-lead ECGs at baseline and Day 1 of each cycle (or as clinically indicated), with central review. AEs were assessed per CTCAE v5.0. Exposure-response analysis using ΔQTcF as the dependent variable and time-matched bleximenib concentrations as the explanatory variable was performed in 139 ALE1001 patients with central ECG data, supported by intensive pharmacokinetic sampling and mean ΔQTcP. Results: Of 334 pts receiving bleximenib across both studies, only one (0.3%) high grade (Grade [Gr] 3) event of QTc prolongation was observed in a pt receiving bleximenib 100mg QD as monotherapy with baseline comorbidities of ongoing cardiomyopathy and hypokalemia. At the recommended Phase 2 dose (RP2D) in ALE1001, a single (1.6%) Gr 1 QTcF prolongation treatment emergent AE (TEAE) occurred that resolved without dose reduction or interruption. In ALE1002, minimal QTcF prolongation TEAEs were reported in pts receiving bleximenib 15–150mg BID in combination with VEN, VEN+AZA, or ‘7+3’.; 8 (4.1%) experienced a QTcF prolongation event. All were low-grade (7 Gr1, 1 Gr2) non serious and did not result in bleximenib dose modifications. No dose dependent trend in QTcF interval increases were apparent across analyses in either study. In ALE1001 central ECG data (n=139), time course of mean change in heart rate (HR) was comparable across different doses. No increase of >10 bpm was observed, with no QTc prolongation seen up to the highest dose explored (2-fold higher exposure vs RP2D). Observations from ALE1002 were similar with no dose-dependent effects on QTc prolongation. ALE1001 exposure-response analysis based on time-matched central ECG data indicated no clinically relevant effect of bleximenib on cardiac repolarization following bleximenib monotherapy at all doses explored. Bleximenib had no clinically significant impact on HR. Conclusions: Administration of bleximenib as monotherapy or in combination with AML-directed therapies did not prolong QTc interval and no cardiac safety signal was identified.",
  "abstract_shown": true,
  "affiliations": [
    "Laura and Isaac Perlmutter Cancer Center at New York University Langone Health, New York, NY, United States",
    "Medical College Of Wisconsin, Milwaukee, WI, United States",
    "City of Hope National Medical Center, Duarte, CA, United States",
    "Clínica Universidad de Navarra, Navarra, Spain",
    "START Madrid-FJD Early Phase Unit, University Hospital Fundación Jiménez Díaz, IIS-FJD, Madrid, Spain",
    "Johnson & Johnson Innovative Medicine, Spring House, PA, United States",
    "Universitätsklinikum Ulm, Ulm, Germany",
    "Hospital Clínic de Barcelona, Barcelona, Spain",
    "Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States",
    "Monash Health and School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia",
    "Aix-Marseille Université, Inserm, CNRS, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille, Marseille, France",
    "Hospital de la Santa Creu i Sant Pau, Barcelona, Spain",
    "Centre Hospitalier Universitaire de Tours, CIC INSERM U1415, Tours, France",
    "MD Anderson Cancer Center, University of Texas, Houston, TX, United States",
    "Universitätsklinikum Leipzig, Leipzig, Germany",
    "Montefiore Einstein Comprehensive Cancer Center, Bronx, NY, United States",
    "Charité – Universitätsmedizin Berlin, Berlin, Germany",
    "Janssen Research & Development, LLC High Wycombe, United Kingdom",
    "ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy",
    "Janssen Research & Development, LLC, Beerse, Belgium",
    "Griffith University and Gold Coast University Hospital, Southport, Australia",
    "IRCCS Istituto Romagnolo per lo Studio de Tuori (IRST), Italy",
    "University College London Hospitals NHS Foundation Trust and UCL/NIHR Clinical Research Facility, London, United Kingdom",
    "Johnson & Johnson Innovative Medicine, Cambridge, MA, United States",
    "Sant’Orsola-Malpighi Polyclinic, Bologna, Italy",
    "University Cancer Institute Toulouse Oncopole, Toulouse, France",
    "Universitätsklinikum TU Dresden, Dresden, Germany",
    "University Hospital Vall d’Hebron, and Experimental Hematology, Vall d’Hebron Institute of Oncology, Barcelona, Spain",
    "Department of Internal Medicine V; Heidelberg University Hospital, Heidelberg, Germany",
    "The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom",
    "Dana-Farber Cancer Institute, Boston, MA, United States",
    "Royal Perth Hospital, Perth, Australia",
    "Johnson & Johnson Innovative Medicine, Raritan, NJ, United States",
    "Westmead Hospital and University of Sydney, Sydney, Australia",
    "Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, Oxford University, United Kingdom",
    "Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Walter and Eliza Hall Institute of Medical Research and University of Melbourne, Melbourne, Australia",
    "Johnson & Johnson Mexico, Mexico",
    "Charité – Universitätsmedizin Berlin, Berlin, Germany, Ghana"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 50,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Maher ABDUL-HAY"
    },
    {
      "affs": [
        1
      ],
      "name": "Sameem ABEDIN"
    },
    {
      "affs": [
        2
      ],
      "name": "Ibrahim ALDOSS"
    },
    {
      "affs": [
        3
      ],
      "name": "Ana PIÉROLA"
    },
    {
      "affs": [
        4
      ],
      "name": "Juan M ALONSO-DOMÍNGUEZ"
    },
    {
      "affs": [
        5
      ],
      "name": "Nikki DASKALAKIS"
    },
    {
      "affs": [
        6
      ],
      "name": "Hartmut DÖHNER"
    },
    {
      "affs": [
        5
      ],
      "name": "Amber D'SOUZA"
    },
    {
      "affs": [
        2
      ],
      "name": "Neil DUNAVIN"
    },
    {
      "affs": [
        7
      ],
      "name": "Jordi ESTEVE"
    },
    {
      "affs": [
        8
      ],
      "name": "Amir T FATHI"
    },
    {
      "affs": [
        9
      ],
      "name": "Pasquale L FEDELE"
    },
    {
      "affs": [
        10
      ],
      "name": "Sylvain GARCIAZ"
    },
    {
      "affs": [
        5
      ],
      "name": "Lucille FERRANTE"
    },
    {
      "affs": [
        11
      ],
      "name": "Ana GARRIDO DIAZ"
    },
    {
      "affs": [
        12
      ],
      "name": "Emmanuel GYAN"
    },
    {
      "affs": [
        5
      ],
      "name": "Nahor HADDISH-BERHANE"
    },
    {
      "affs": [
        13
      ],
      "name": "Elias J JABBOUR"
    },
    {
      "affs": [
        14
      ],
      "name": "Madlen JENTZSCH"
    },
    {
      "affs": [
        15
      ],
      "name": "Marina KONOPLEVA"
    },
    {
      "affs": [
        16
      ],
      "name": "Jan KRöNKE"
    },
    {
      "affs": [
        17
      ],
      "name": "Oliver LOMAS"
    },
    {
      "affs": [
        5
      ],
      "name": "Anita J KUMAR"
    },
    {
      "affs": [
        5
      ],
      "name": "Dandan LUO"
    },
    {
      "affs": [
        5
      ],
      "name": "Christina LOEFGREN"
    },
    {
      "affs": [
        18
      ],
      "name": "Valentina MANCINI"
    },
    {
      "affs": [
        19
      ],
      "name": "Anna MITSELOS"
    },
    {
      "affs": [
        4
      ],
      "name": "Daniel MORILLO"
    },
    {
      "affs": [
        20
      ],
      "name": "Teng F NG"
    },
    {
      "affs": [
        21
      ],
      "name": "Marianna NORATA"
    },
    {
      "affs": [
        22
      ],
      "name": "Jenny O'NIONS"
    },
    {
      "affs": [
        23
      ],
      "name": "Kathryn PACKMAN"
    },
    {
      "affs": [
        24
      ],
      "name": "Cristina PAPAYANNIDIS"
    },
    {
      "affs": [
        25
      ],
      "name": "Christian RECHER"
    },
    {
      "affs": [
        19
      ],
      "name": "Ulrike PHILIPPAR"
    },
    {
      "affs": [
        19
      ],
      "name": "Giorgos PSARROS"
    },
    {
      "affs": [
        26
      ],
      "name": "Christoph RöLLIG"
    },
    {
      "affs": [
        27
      ],
      "name": "Olga SALAMERO"
    },
    {
      "affs": [
        28
      ],
      "name": "Tim SAUER"
    },
    {
      "affs": [
        29
      ],
      "name": "Emma SEARLE"
    },
    {
      "affs": [
        5
      ],
      "name": "Prathap N SHASTRI"
    },
    {
      "affs": [
        30
      ],
      "name": "Richard STONE"
    },
    {
      "affs": [
        31
      ],
      "name": "Peter TAN"
    },
    {
      "affs": [
        32
      ],
      "name": "Tao SUN"
    },
    {
      "affs": [
        33
      ],
      "name": "Lachlin VAUGHAN"
    },
    {
      "affs": [
        4
      ],
      "name": "Gala VEGA"
    },
    {
      "affs": [
        34
      ],
      "name": "Paresh VYAS"
    },
    {
      "affs": [
        35
      ],
      "name": "Andrew H WEI"
    },
    {
      "affs": [
        36
      ],
      "name": "Monserrat ROJAS"
    },
    {
      "affs": [
        37
      ],
      "name": "Marie Luise HüTTER-KRÖNKE"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/bxh317gkdz08s.bib",
  "cited_by": 0,
  "doi": "10.1016/j.htct.2026.107906",
  "fulltext_url": "http://www.sciencedirect.com/science/article/pii/S2531137926016536",
  "id": "bxh317gkdz08s",
  "issns": [
    "2531-1379",
    "2531-1387"
  ],
  "landing_url": "https://doi.org/10.1016/j.htct.2026.107906",
  "language": "en",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "lcc",
      "RC633-647.5"
    ],
    [
      "openalex",
      "2720|Acute Myeloid Leukemia Research"
    ]
  ],
  "openalex": "W7223087167",
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-23",
  "publisher": "Elsevier",
  "ris": "https://research.draconitic.com/paper/bxh317gkdz08s.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T13:43:27Z",
      "native_id": "ab164a79f6924414b7ab9228ff318dbf",
      "source": "doaj",
      "url": "https://doi.org/10.1016/j.htct.2026.107906"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "lcc:RC633-647.5",
      "subfield": "endocrinology-metabolism"
    }
  ],
  "title": "NO EVIDENCE OF QTC INTERVAL PROLONGATION WITH THE MENIN INHIBITOR BLEXIMENIB WHEN GIVEN AS MONOTHERAPY OR IN COMBINATION WITH ACUTE MYELOID LEUKEMIA AML-DIRECTED THERAPIES FOR KMT2A OR NPM1 ALTERED AML",
  "title_text": "NO EVIDENCE OF QTC INTERVAL PROLONGATION WITH THE MENIN INHIBITOR BLEXIMENIB WHEN GIVEN AS MONOTHERAPY OR IN COMBINATION WITH ACUTE MYELOID LEUKEMIA AML-DIRECTED THERAPIES FOR KMT2A OR NPM1 ALTERED AML",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T13:43:27Z",
  "url": "https://research.draconitic.com/paper/bxh317gkdz08s",
  "venue": "Hematology, Transfusion and Cell Therapy",
  "versions": []
}